Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of “Hold” from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average recommendation of “Hold” by the six brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

Several analysts recently issued reports on the company. JMP Securities cut their price target on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 7th. HC Wainwright cut their target price on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. Finally, StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, insider Tara Lynn Kieffer sold 7,266 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $12.33, for a total value of $89,589.78. Following the completion of the transaction, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Scott T. Rottinghaus sold 4,299 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the sale, the insider now owns 23,988 shares of the company’s stock, valued at $361,499.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Tara Lynn Kieffer sold 7,266 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $12.33, for a total value of $89,589.78. Following the completion of the sale, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The disclosure for this sale can be found here. Insiders have sold 16,940 shares of company stock valued at $246,181 in the last quarter. Corporate insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its stake in Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,281 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at about $35,000. State Board of Administration of Florida Retirement System bought a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at about $118,000. Quest Partners LLC acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $146,000. Finally, Strs Ohio raised its holdings in shares of Enanta Pharmaceuticals by 20.6% in the 4th quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 3,200 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $13.90 on Monday. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $20.04. The company has a 50-day simple moving average of $13.53 and a 200-day simple moving average of $13.74. The firm has a market capitalization of $294.40 million, a PE ratio of -2.23 and a beta of 0.60.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.21). The business had revenue of $17.05 million during the quarter, compared to the consensus estimate of $16.47 million. Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. Equities analysts forecast that Enanta Pharmaceuticals will post -5.95 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.